IL2 and systemic lupus erythematosus: In a subsequent randomized, placebo-controlled trial of 60 patients with active SLE by the same group [64], the same IL-2 treatment regime as in the open-labelled study [63] resulted in 55.17% SRI-4 response in the IL-2 group compared with 30% in the placebo group at week 12.